News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

4 Ways Gilead Sciences, Inc. (GILD)’s Earnings Will Impact Every American



7/24/2014 6:24:51 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Today’s earnings report from Gilead Sciences will be closely watched on both Wall Street and Capitol Hill, where the argument about how much the world’s second-most-valuable biotech company should charge for its new $84,000 hepatitis C drug Sovaldi is getting more and more heated. For most people, though, the arguments that matter aren’t about whether Gilead beats rumor-mill estimates that it may have sold $4 billion of Sovaldi this past quarter. The reader mail that came in when I wrote about my own experience as one of the first Sovaldi patients in April is all about the new consumer-medical world Sovaldi heralds: patients pay more of the bill, consumers shop and bargain to hold down costs, and the phrase “insurance covers it” will drive ever-fewer decisions.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Market Watch


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES